CMS establishes unique J-code for Bendeka Injection

Provides access for patients and streamlined reimbursement.

The new J-code provides reimbursement coding clarity to outpatient facilities and physicians that administer Bendeka, facilitating access for patients and Medicare, Medicaid and commercial insurance reimbursement.

“We are pleased that CMS recognized that the unique formulation and delivery mechanism offered by Bendeka required separate recognition from other bendamustine products currently on the market. We expect the new J-code will provide greater access for patients, facilitate reimbursement and enable greater adoption of BENDEKA in the market,” said Scott Tarriff, President and CEO of Eagle Pharmaceuticals.

“This is an important milestone for Teva as we continue to advance our bendamustine franchise with Bendeka,” said Paul Rittman, Senior Vice President and General Manager, Teva Oncology. “We are committed to serving patients in need of this important therapy and are pleased that a unique J-code has been established to assist providers in obtaining reimbursement for Bendeka.”